Sign InBreakout Stocks of Week 30 @ NASDAQ
NASDAQ was down last week (week 29) by -2.90% ending at 25,520.24 points after falling -761.36 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Forbright, Inc. Class A Common Stock NASDAQ:FRBT. This stock has had a buy signal since Jul 17, 2026 when the price was $19.05 , but have so far fallen 0% to $19.05. Some other companies are on our watchlist to, among these are Sadot Group Inc. NASDAQ:SDOT Aquestive Therapeutics Inc. NASDAQ:AQST Iqm Quantum Computers Oyj NASDAQ:IQMX and FIRST TRUST SSI STRATEGIC CONVERTIBLE SECURITIES ETF NASDAQ:FCVT which all got a breakout pattern emerging.
| Date | Company | Price | Week 30 |
|---|---|---|---|
| Forbright, Inc. Class A Common Stock | $19.05 | $19.61 | 2.94% |
| Sadot Group Inc. | $25.30 | $17.52 | -30.75% |
| Aquestive Therapeutics Inc. | $4.12 | $3.68 | -10.68% |
| Iqm Quantum Computers Oyj | $10.70 | $10.75 | 0.467% |
| First Trust Ssi Strategic Convertible Securities E... | $49.37 | $49.33 | -0.0913% |
The Forbright, Inc. Class A Common Stock stock price gained 1.98% on the last trading day (Friday, 17th Jul 2026), rising from $18.68 to $19.05. During the last trading day the stock fluctuated 8.20% from a day low at $18.29 to a day high of $19.79. The price has been going up and down for this period, and there has been a 1.6% gain for the last 2 weeks. Volume fell on the last day by -109 thousand shares and in total, 129 thousand shares were bought and sold for approximately $2.45 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
On Jul 06, 2026, it was reported that Cowen & Co. gave FRBT a "Buy" grade with a "initialise" action.
Forbright, Inc. Class A Common Stock holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
The Sadot Group Inc. stock price gained 77.54% on the last trading day (Friday, 17th Jul 2026), rising from $14.25 to $25.30. During the last trading day the stock fluctuated 59.64% from a day low at $19.40 to a day high of $30.97. The price has fallen in 8 of the last 10 days and is down by -49.95% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 23 million more shares were traded than the day before. In total, 24 million shares were bought and sold for approximately $601.61 million.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Sadot Group Inc. stock to perform well in the short-term.
The Aquestive Therapeutics Inc. stock price gained 4.57% on the last trading day (Friday, 17th Jul 2026), rising from $3.94 to $4.12. During the last trading day the stock fluctuated 9.07% from a day low at $3.81 to a day high of $4.16. The price has fallen in 7 of the last 10 days and is down by -1.44% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 437 thousand more shares were traded than the day before. In total, 2 million shares were bought and sold for approximately $9.67 million.
On Feb 02, 2026, it was reported that Oppenheimer gave AQST a "Outperform" grade with a "hold" action.
Several short-term signals are positive and we conclude that the current level may hold a buying opportunity, as there is a fair chance for Aquestive Therapeutics Inc. stock to perform well in the short-term period.
About Aquestive Therapeutics Inc.:
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
The Iqm Quantum Computers Oyj stock price gained 0.753% on the last trading day (Friday, 17th Jul 2026), rising from $10.62 to $10.70. During the last trading day the stock fluctuated 7.69% from a day low at $10.14 to a day high of $10.92. The price has been going up and down for this period, and there has been a -17.88% loss for the last 2 weeks. Volume fell on the last day by -159 thousand shares and in total, 337 thousand shares were bought and sold for approximately $3.60 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Several of the signals/indicators are negative, and we believe that this will affect on the development for the next days and maybe possible weeks. However, over time, we think that today's level holds a possible buying opportunity and that the price will be higher during or at the end of this 3-month period.
FIRST TRUST SSI STRATEGIC CONVERTIBLE SECURITIES ETF
NASDAQ:FCVTThe FIRST TRUST SSI STRATEGIC CS ETF price gained 0.0874% on the last trading day (Friday, 17th Jul 2026), rising from $49.33 to $49.37. During the last trading day the ETF fluctuated 1.98% from a day low at $48.49 to a day high of $49.45. The price has been going up and down for this period, and there has been a -4.11% loss for the last 2 weeks. Volume fell on the last day by -8 thousand shares and in total, 41 thousand shares were bought and sold for approximately $2.03 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
FIRST TRUST SSI STRATEGIC CS holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
BIIB
$202.19
|
1.69% | Jul 24 |
|
A
AVS
$7.74
|
0.388% | Jul 24 |
IMMR
$6.60
|
16.06% | Jul 23 |
|
S
SW
$43.71
|
16.22% | Jul 23 |
TSCO
$30.32
|
3.76% | Jul 23 |
